Amid heightened public concern, the cost of prescription drugs is a focus of attention by the Biden administration and lawmakers in Congress and state capitals. Proposed actions range from allowing Medicare to negotiate the prices of certain drugs to limiting some drug price increases to inflation and capping out of pocket costs for Medicare beneficiaries in Part D, among other initiatives. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.
Featured Prescription Drugs Resources
Report See More
Related Prescription Drugs Resources
- Insulin Out-of-Pocket Costs in Medicare Part D
- Prices Increased Faster Than Inflation for Half of all Drugs Covered by Medicare in 2020
- Out-of-pocket spending on insulin among people with private insurance
- How Do Prescription Drug Costs in the United States Compare to Other Countries?
- Public Opinion on Prescription Drugs and Their Prices
- Insulin Costs and Coverage in Medicare Part D
- Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act
- The Public Weighs In On Medicare Drug Negotiations
- Potential Savings for Medicare Part D Enrollees Under Proposals to Add a Hard Cap on Out-of-Pocket Spending
- Medicare Part B Drugs: Cost Implications for Beneficiaries in Traditional Medicare and Medicare Advantage
- 10 FAQs on Prescription Drug Importation
- Medicaid Outpatient Prescription Drug Trends During the COVID-19 Pandemic
- Prescription Drug Rebates, Explained
- Who is most likely to have high prescription drug costs?
- Latest News on Prescription Drugs from Kaiser Health News
How Would the Prescription Drug Provisions in the Senate Reconciliation Proposal Affect Medicare Beneficiaries?
The brief provides a quick explainer of the prescription drug provisions in legislative text released by the Senate Finance Committee to be included in a forthcoming reconciliation bill and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.
Issue Brief See More
- view as grid
- view as list
This report describes and reviews various options to address prescription drug spending growth, including a description of each cost-containment strategy, its use by private or public payers, and a discussion of known evidence about its effectiveness or cost-saving potential. It was prepared for the Kaiser Family Foundation by Jack Hoadley,…Report Read More
National Survey on Consumers’ Experiences With Patient Safety and Quality Information — ToplinesThis document includes the complete toplines from a national survey assessing Americans’ perceptions about the quality of health care, their awareness and reported usage of information in making their health care choices, and their experiences with their health…Poll Finding Read More
State Financing of the Medicare Drug Benefit: New Data on the “Clawback”Beginning in 2006, states will be obligated to finance part of the new Medicare prescription drug benefit via a monthly “clawback” payment to the federal government. This issue update analyzes the latest data and provides an overview of the…Issue Brief Read More
This report, Reactions to the New Medicare Drug Law, produced jointly by a bipartisan team of pollsters from Public Opinion Strategies and Peter D. Hart Research Associates, presents key findings from ten focus groups of people on Medicare in three cities: Pittsburgh, PA; Kansas City, KS, and Washington, DC. The…Report Read More
USA Today/Kaiser Family Foundation/Harvard School of Public Health Survey: The Public on Prescription Drugs and Pharmaceutical Companies: Summary and Charts
This document provides key findings from a USA Today/Kaiser/Harvard survey examining Americans’ views on, and experiences with, prescription drugs and the pharmaceutical industry, including drug costs, advertisements, safety issues, government regulation and medical research. Summary and Charts (.pdf)Poll Finding Read More
This synthesis of key findings from analysis presented in a series of eight Medicare Part D 2008 Data Spotlights describes key features of stand-alone prescription drug plans offered in 2008 and trends since 2006. The synthesis covers a range of topics, including premiums, the coverage gap, benefit design, cost sharing,…Issue Brief Read More
Prescription drugs have become an integral part of medical practice – they help keep people healthy and save lives. But rising prescription drug costs have placed a growing burden on consumers, employers, and public programs. The issue of drug coverage for seniors under Medicare has moved to center stage in…Fact Sheet Read More
This issue brief, prepared as part of the National ADAP Monitoring Project, examines how ADAPs purchase and dispense drugs, and the drug discount programs that assist states in containing ADAP costs. For more information on the series see the National ADAP Monitoring Project page. Issue BriefIssue Brief Read More
Testimony by Patricia Neuman, Sc.D., vice president and director of the Foundation’s Medicare Policy Project, for the House Committee on Energy and Commerce, Subcommittee on Health, hearing on Creating a Medicare Prescription Drug Benefit: begins with a brief review of existing sources of prescription drug coverage for the Medicare population…Event Read More
This chartbook provides information on key trends in the health care marketplace including health spending, the structure of the health care marketplace, and health plan and provider relationships. It highlights data on health plan enrollment, premiums, and benefits, and the implications of health market trends for consumers and the safety…Report Read More